Catalyst Pharmaceutical Partners, Inc. · Coral Gables, FL United States (NASDAQ: CPRX)
| 355 Alhambra Circle, Ste. 1370 | Phone: 305-529-2522 |
| Coral Gables, FL | Fax: 305-529-0933 |
| 33134 | |
| United States | 
Map This Company |
Catalyst Pharmaceutical Partners, Inc. Rankings
More Companies in These Related Industries: Pharmaceutical Preparation MfgCompany Description
Catalyst Pharmaceutical Partners may help certain addicts kick the habit. The development-stage company's lead candidate, CPP-109 (based on the chemical compound vigabatrin), is in clinical studies for the treatment of cocaine and methamphetamine addiction. The drug is designed to be readily absorbed into the central nervous system, preventing the perception of pleasure that results from dramatic increases in dopamine caused by cocaine and meth use. Contract manufacturer Pharmaceutics International is supplying CPP-109 for use in upcoming clinical trials and may also be contracted for future commercial supplies should the drug become approved in the US.
Catalyst Pharmaceutical Partners, Inc. Reports
No subscription, no problem.
Download presentation-ready reports. From company profiles to the competitive landscape, Hoover's offers immediate access to individual reports.
Financials
| Company Type | Public - NASDAQ: CPRX Single Location |
|---|---|
| Fiscal Year-End | December |
| 2011 Employees | 6 |
Executives
7 executives listed for Catalyst Pharmaceutical Partners, Inc.'s Coral Gables, FL location.
| Chairman, President, and CEO | Patrick McEnany | |
|---|---|---|
| COO and Chief Scientific Officer | Steven Miller | |
| VP, CFO, and Treasurer | Jack Weinstein |